| Name | Title | Contact Details |
|---|---|---|
Christian Ricciardiello |
Senior Vice President and General Counsel | Profile |
Mercy General Health Partners is a Muskegon, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
AxioMed was founded to advance the standard of care for patients with degenerative spine conditions by progressing spine technology beyond fusion and first-generation artificial discs. Led by an experienced surgeon team and utilizing patented viscoelastic polymer technology, AxioMed has developed the next generation of artificial discs.
Boulder is a digital health platform expanding access to effective treatment for opiate use. We aim to move the behavioral health industry forward by offering dramatically better experiences for patients and their care teams.
Oxford Medical Simulation delivers virtual reality medical simulation - training healthcare professionals to provide consistently world-class patient management without risking lives. Medical simulation has become central to medical training and is highly effective. However, it is expensive, low throughput and not widely accessible. Healthcare workers therefore struggle to get the training they need to deliver optimal patient care. We remove these barriers by offering virtual reality training scenarios. These provide a completely safe, controlled-stress learning environment for all healthcare professionals. The focus is on clinical decision-making under pressure, crisis resource management, team interaction and patient engagement. Our fast-paced, repeatable, real-life scenarios can deliver consistently excellent, standardised clinical training to doctors and nurses to improve patient care.
Neuralstem is a dual platform regenerative medicine company. The company`s technology enables the production of regionally specific, physiologically relevant neural stem cells for therapeutic use for the treatment of central nervous system (CNS) diseases and has enabled the discovery of a library of patented small molecule neurogenic compounds to treat psychological and cognitive disorders. Neuralstem`s small molecule drug discovery program screens human neural stem cell lines for compounds that may stimulate neurogenesis in the brain, possibly reversing pathologies associated with certain CNS conditions. The company`s lead compound, NSI-189, has completed FDA Phase Ia and Ib safety trials for the treatment of major depressive disorder (MDD). Neuralstem is expecting to launch a Phase II study for MDD in 2015. Neuralstem`s first stem cell therapy product, NSI-566, a spinal cord-derived neural stem cell line, is in ongoing clinical trials to treat amyotrophic lateral sclerosis (ALS, or Lou Gehrig`s disease), for which it has received orphan status designation by the FDA. Dosing in a phase IIa trial was completed in July, 2014. The next trial is anticipated to commence in 2015. In addition to ALS, the company is conducting an NSI-566 Phase I trial in chronic spinal cord injury, with NSI-566 clinical development also underway to treat ischemic